Study examined outcomes of patients with MCL who relapse after treatment of BTK inhibitors.
Home / Resource Library / Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis